Over 1 million people in North America live with Crohn’s disease (CD) and nearly 25% are diagnosed before 20 years of age.1 Patients with pediatric-onset CD endure a lifelong disease burden with high rates of disease progression, increased risk of recurrent surgery and decreased height potential.2 Over the past two decades, there has been a paradigm shift in the treatment of CD with the development of biologic agents.3,4 While biologics have shown to improve short-term outcomes, it has been difficult to show the long-term benefit of biologic therapy from standard trials. A team of clinicians, statisticians and computer analysts have come together…
Author: Praveen Suthrum
The Bradenton, FL-based gastroenterology healthcare provider Florida Digestive Health Specialists (FDHS) has recently started notifying more than 212,000 patients that some of their protected health information has been exposed in a December 2020 cyberattack. Notification letters were sent to affected individuals on December 27, 2021, by attorney Jason M. Schwent of Clark Hill. The letters explain that suspicious activity was detected in an employee email account on December 16, 2020, which involved an unauthorized individual sending emails from that account.
In 2017, the number of women students entering medical school surpassed that of men.1 However, the future generation of women doctors is unlikely to be paid the same as their male colleagues for equal work unless something changes in health care. About 34% of gastroenterology fellows are women,2 and there are increasing proportions of women in all academic and community practices, as well as in leadership positions.
GI, liver, and pancreatic diseases cost the U.S. health care system about $120B per year and account for approximately 250,000 annual deaths, according to a “conservative” estimate from a recent analysis. These figures emphasize the need for more research funding in the area, along with additional clinical and public health initiatives, reported lead author Anne F. Peery, MD, of the University of North Carolina School of Medicine, Chapel Hill, and colleagues.
As we look back, we can certainly say that 2021 has been a productive year for gut microbiome research. In this last post of the year, we bring you key articles from our blog and studies on major advances in the role of the gut microbiome in maintaining health and helping to manage gut and immune-related diseases. We will also look at the therapeutic potential of probiotics, prebiotics and postbiotics for your clinical practice.
The goal of artificial intelligence in colonoscopy is to improve adenoma detection rate and reduce interval colorectal cancer. Artificial intelligence in polyp detection during colonoscopy has evolved tremendously over the last decade mainly due to the implementation of neural networks. Computer aided detection (CADe) utilizing neural networks allows real time detection of polyps and adenomas. Current CADe systems are built in single centers by multidisciplinary teams and have only been utilized in limited clinical research studies.
This year’s published gastrointestinal (GI)-related literature was, as usual, abundant. As many of us resumed clinical routines and office hours more typical of pre-pandemic years, we can be forgiven for letting some of the new publications slip by. Blink and you may have missed updated guidelines from the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG), expert reviews on various disorders, or recent clinical trials about prevalent GI cancers.
Miami-based Gastro Health had a strong year, adding nine practices and expanding its reach in Florida, Ohio and Virginia. Here were 11 Gastro Health moves in 2021: 1. Gastro Health signed a definitive agreement to partner with North Miami, Fla.-based Digestive Care Center, the medical group said Nov. 17 in a news release shared with Becker’s. 2. The company was recognized by the eHealthcare Leadership Awards for its website’s doctor directory, the company said Nov. 9.
At least 10 private equity-backed healthcare providers in the U.S. will go public in 2022, up from six in 2021, according to a Pitchbook report released Dec. 16. 5 things to know: 1. Private equity firms are going after public listings for their companies more than they ever have before, according to the report. 2. Value-based care — when providers are reimbursed depending on the patient outcome instead of the volume of services — is becoming more popular and has bipartisan support. Arlington, Va.-based Privia Health and Long Beach, Calif.-based Agilon Health, which have both adopted value-based care and are backed by…
By Landon Gray Originally published in our sister publication, Gastroenterology & Endoscopy News Phathom announced the FDA approval of vonoprazan tablets, amoxicillin capsules, clarithromycin tablets (Voquezna Triple PAK, Phathom) and vonoprazan tablets, amoxicillin capsules (Voquezna Dual PAK, Phathom) for treatment of Helicobacter pylori infection in adults.